{"id":2164,"date":"2010-03-01T12:04:00","date_gmt":"2010-03-01T11:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2010\/perioperatives-arzneimittelmanagement-hemmung-der-thrombozytenfunktion-bei-kardiovaskulaeren-krankheiten"},"modified":"2022-03-17T14:11:47","modified_gmt":"2022-03-17T13:11:47","slug":"perioperatives-arzneimittelmanagement-hemmung-der-thrombozytenfunktion-bei-kardiovaskulaeren-krankheiten","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2010\/perioperatives-arzneimittelmanagement-hemmung-der-thrombozytenfunktion-bei-kardiovaskulaeren-krankheiten","title":{"rendered":"Perioperatives Arzneimittelmanagement: Hemmung der Thrombozytenfunktion bei kardiovaskul\u00e4ren Krankheiten"},"content":{"rendered":"<p>Viele Patienten, die operiert werden m\u00fcssen, haben kardiovaskul\u00e4re Krankheiten und erhalten deswegen Hemmer der Thrombozytenfunktion. Speziell Patienten, bei denen Gef\u00e4\u00dfoperationen geplant sind, und Diabetiker haben h\u00e4ufig eine Koronare Herzkrankheit (KHK; Pr\u00e4valenz 30-50%; 1). Die meisten erhalten Azetylsalizyls\u00e4ure (ASS) zur Sekund\u00e4rprophylaxe, einige auch eine duale Hemmung der Thrombozytenfunktion mit ASS plus Clopidogrel (Iscover\u00ae, Plavix\u00ae), so z.B. [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Viele Patienten, die operiert werden m\u00fcssen, haben kardiovaskul\u00e4re Krankheiten und erhalten deswegen Hemmer der Thrombozytenfunktion. Speziell Patienten, bei denen Gef\u00e4\u00dfoperationen geplant sind, und Diabetiker haben h\u00e4ufig eine Koronare Herzkrankheit (KHK; Pr\u00e4valenz 30-50%; 1). Die meisten erhalten Azetylsalizyls\u00e4ure (ASS) zur Sekund\u00e4rprophylaxe, einige auch eine duale Hemmung der Thrombozytenfunktion mit ASS plus Clopidogrel (Iscover\u00ae, Plavix\u00ae), so z.B. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[74,495,255,77,76,2088,3124,73,1170,730,729,98,71,1172,498,257,65,1408,1033,882,727,725],"class_list":["post-2164","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acetylsalicylsaeure","tag-angina-pectoris","tag-arzneimittel","tag-ass","tag-azetylsalizylsaeure","tag-blutungsrisiko","tag-bridging","tag-clopidogrel","tag-eptifibatid","tag-gp-iib-iiia-rezeptor-antagonisten","tag-gp-iib-iiia-rezeptor-blocker","tag-heparin","tag-herzinfarkt","tag-koronar-stent","tag-koronare-herzkrankheit","tag-medikamente","tag-myokardinfarkt","tag-operationen","tag-prasugrel","tag-stent","tag-thrombozytenaggregationshemmer","tag-tirofiban"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2164"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2164\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}